Background and Aim to Read: We report the results of a bicuspid expanded
| INTRODUCTION
Conduit selection for right ventricular outflow tract (RVOT) reconstruction is a major challenge in the treatment of congenital heart diseases with RVOT obstruction. Xenografts and homografts have been used for long time, but their longevity is limited due to early degeneration or calcification especially in young patients. [1] [2] [3] [4] [5] [6] Moreover, the availability of these conduits can be limited.
Replacement with a bioprosthetic or mechanical valve is sometimes required when the patient reaches late adolescence or early adulthood. However, for neonates there is no ideal conduit. To expand current conduit alternatives, we developed a bicuspid expanded polytetrafluoroethylene (ePTFE) valved conduit that is composed of a standard stretch PTFE graft and bicuspid cusps that are made of a thin (0.1 mm) PTFE membrane (W.L. Gore & Associates, Inc., Flagstaff, AZ). When the ePTFE membrane was used, significant calcification was not demonstrated in monocuspid, bicuspid, and tricuspid valved RVOT reconstruction. [7] [8] [9] [10] The purpose of this study is to investigate the long-term functional results of this valved conduit.
| PATIENTS AND METHODS
We retrospectively reviewed data of patients who underwent RVOT reconstruction using an ePTFE bicuspid valved conduit between November 2005 and February 2009 at Pusan National University Hospital and Pusan National University Children Hospital. The patients' clinical records were reviewed for preoperative, intraoperative, post-operative, and follow-up data. The study was approved by the local institutional review board.
| Patient profile
Twelve bicuspid ePTFE valved conduits were implanted in 12 patients 
| Surgical technique
We used two techniques to make the bicuspid valved conduit, as shown in Figures 1 and 2 . In one technique, which was used for the initial two patients, two curvilineal incisions were made, and appropriately designed valved cusps (with an ePTFE membrane that was 0.1-mm thick) were introduced into the lumen of the conduit through separate incisions. The cusps were attached to the incisions by closing the incision together with the cusps (Figure 1 ). In the other technique, which was applied to the remaining 10 patients, we divided the conduit into two parts: the valve and the conduit. We made two longitudinal incisions of appropriate lengths at the bilateral sides of the valve portion. The appropriately designed two layers of the ePTFE membrane that had commissures were put into the conduit through the incisions, and the two incisions were closed together with the ePTFE membranes to attach the valve cusp to the conduit. Then this valve portion was connected to the beveled end of the conduit portion by suturing the cusp membrane together, after the two layers of the membrane were opened. The bicuspid The conduit was prepared under aseptic conditions in an operating room, and was used after ethylene oxide gas sterilization was performed.
The smallest conduit that could be manufactured using this technique was 12 mm in diameter. Figures 1 and 2 show how the valved conduit was made and Figure 3 shows how the cups were designed.
| Postoperative management
All patients received heparin immediately after the cessation of postoperative bleeding. Anticoagulation with coumadin was then started after oral intake resumed and continued for 3 months. Aspirin was administered indefinitely thereafter.
| Follow-up
Follow-up data were obtained through the patients' medical records.
The function of the valved conduit was evaluated using twodimensionial echocardiography data that were described in the medical records, and was evaluated for conduit thrombosis, conduit pressure gradient, and degree of pulmonary valve regurgitation. There was 100% patient follow-up.
The mean follow-up duration was 88.0 ± 35.9 months (range:
14.0-130.0 months, median 100.4 months). We defined valved conduit "failure" when the valved conduit gradient was higher than 50 mmHg and when there was greater than moderate valve regurgitation. Their early results were excellent, but their follow-up duration was only 6.2 ± 3.9 months.
| Statistical analysis
Miyazaki et al 9 produced an excellent ePTFE membrane tricuspid valved conduit with bulging sinuses, but we believe that this method is technically demanding and less reproducible. In particular, the quality of the valves depend on the skill level of the surgeon. Valve cusps that are made using the over-and-over suture technique could also have wrinkles at the cusps, which can produce furrows. These small furrows produce a potential place for collecting fibrin or cells that could hinder cusp motion.
We have simplified the technique of making an ePTFE valved conduit to make it more durable and reproducible. We avoided the over-and-over suturing technique, which can be technically demanding and makes wrinkles on the cusp. Instead, we attached the valve cusps to the conduit with the "incision and suture" technique, in which two incisions were made in the conduit and the incisions were closed together with the ePTFE membrane. Furthermore, the valved conduit that was created by our second technique was designed to have some angulation to fit the natural angulation between the right ventricle and main pulmonary artery.
In Miyazaki et al's 11 report of the tricuspid ePTFE valved conduit with a bulging sinus, the rate of freedom from reoperation at 10 years was 95.4%; however, the mean follow-up duration was only 3.6 years.
Shinkawa et al 12 showed that the 5-year freedom from conduit reoperation rate was 92.7% when using a tricuspid valved conduit, and the rate of freedom from severe conduit insufficiency or a gradient greater than a 50 mmHg was 74.8%. In our series, the two patients who required conduit reoperation within 2 years had conduit compression by the sternum. This is probably related to the failure of the conduit to In conclusion, a bicuspid ePTFE valved conduit can be used in young patients with reasonable durability. However, pressure gradients across the conduit valve tends to increase over time, which limits the durability in these patients. Percutaneous options using the Melody and modified stented bovine bioprostheses may have a role to play in dealing with these stenotic conduit valves.
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